Galapagoss mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary healthy andpatient cells, the company discovers which proteins play a key role in diseases such as rheumatoid arthritis, inflammatory bowel disease, and fibrosis.
Oncology drugs developed through a biomarker-guided precision medicine design are 38% more likely to be commercialized. But success relies on following a plan from the start — learn how in this free whitepaper
BioEcho develops single-spin and 96-well kits for the isolation of DNA. Their proprietary EchoLUTION single-step technology avoids the use of inhibitory process reagents resulting in increased sensitivity and reliability of downstream analyses. Therefore, the risk of inhibition or complete failure of PCR applications is eliminated. The process does not require washing steps and is significantly faster than commonly used bind-wash-elute methods.
Small- and medium-size European companies face the challenge of establishing global B2B activities in order to access relevant markets along the drug development value chain. YUMABs flexible business model for the development of fully human antibodies attracts corporations overseas and facilitates international partnerships.
The 9th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.
High-potency drugs present numerous opportunities for improved drug selectivity, efficacy and safety profiles, and represent a growing area of global development focus, for applications such as oncology and hormone-based treatments. Although this class of molecules offers numerous benefits to patients, they require particular care and attention in ensuring the safety for those involved in their manufacture and handling.
Six times as many decision-makers attended the 3rd European Chemistry Partnering today- compared to the initial event two years ago: with participants from Brazil, Morocco and Australia, all six continents were represented for the first time. More than 2,000 partnering meetings formed the basis of interdisciplinary exchanges regarding innovation. In addition, there were countless discussions in the exhibition area, at the speaker corners and during the many networking opportunities.
Leading global supplier of materials, Goodfellow, has collaborated with a number of major international companies to provide research materials in several industry sectors.
DIA Europe is more than a traditional meeting. It’s a chance to learn, engage, and grow as a healthcare professional alongside thousands of cross-functional collaborative leaders.